AEON Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AEON NYSE American 2836 www.aeonbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AEON Biopharma, Inc.

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 13th, 2024 9:05 pm
AEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory Meeting - Sep 30th, 2024 12:00 pm
AEON Biopharma, Inc. (AEON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Aug 21st, 2024 1:55 pm
AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - Aug 19th, 2024 8:05 pm
AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Aug 12th, 2024 8:05 pm
AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450 - Jul 9th, 2024 12:00 pm
Down -64.16% in 4 Weeks, Here's Why AEON Biopharma, Inc. (AEON) Looks Ripe for a Turnaround - May 29th, 2024 1:35 pm
AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan - May 29th, 2024 12:00 pm
AEON Biopharma Reports First Quarter 2024 Financial Results - May 14th, 2024 8:05 pm
AEON Biopharma, Inc. (AEON) Loses -79.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - May 9th, 2024 1:35 pm
AEON Biopharma Provides Update on Development Pipeline - May 9th, 2024 12:00 pm
US Equity Markets Close Higher Friday Following Weak Jobs Report - May 3rd, 2024 8:08 pm
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine - May 3rd, 2024 11:00 am
Here's Why AEON Biopharma, Inc. (AEON) Is a Great 'Buy the Bottom' Stock Now - Apr 19th, 2024 1:55 pm
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants - Mar 31st, 2024 2:53 am
AEON Biopharma Announces Redemption of Public Warrants - Mar 29th, 2024 8:15 pm
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results - Mar 29th, 2024 7:45 pm
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine - Mar 19th, 2024 8:30 pm
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements - Mar 19th, 2024 8:29 pm
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference - Jan 18th, 2024 9:05 pm